Literature DB >> 31774291

Untargeted Serum Metabolic Profiling by Comprehensive Two-Dimensional Gas Chromatography-High-Resolution Time-of-Flight Mass Spectrometry.

Nicolas Di Giovanni1, Marie-Alice Meuwis2, Edouard Louis2, Jean-François Focant1.   

Abstract

While many laboratories take appropriate care, there are still cases where the performances of untargeted profiling methods suffer from a lack of design, control, and articulation of the various steps involved. This is particularly harmful to modern comprehensive analytical instrumentations that otherwise provide an unprecedented coverage of complex matrices. In this work, we present a global analytical workflow based on comprehensive two-dimensional gas chromatography coupled to high-resolution time-of-flight mass spectrometry. It was optimized for sample preparation and chromatographic separation and validated on in-house quality control (QC) and NIST SRM 1950 samples. It also includes a QC procedure, a multiapproach data (pre)processing workflow, and an original bias control procedure. Compounds of interest were identified using mass, retention, and biological information. As a proof of concept, 35 serum samples representing three subgroups of Crohn's disease (with high, low, and quiescent endoscopic activity) were analyzed along with 33 healthy controls. This led to the selection of 33 unique candidate biomarkers able to classify the Crohn's disease and healthy samples with an orthogonal partial least-squares discriminant analysis Q2 of 0.48 and a receiver-operating-characteristic area under the curve of 0.85 (100% sensitivity and 82% specificity in cross validation). Fifteen of these 33 candidates were reliably annotated (Metabolomics Standards Initiative level 2).

Entities:  

Keywords:  Crohn’s disease; GC×GC; QC system; comprehensive gas chromatography; inflammatory bowel disease; untargeted metabolomics

Mesh:

Substances:

Year:  2019        PMID: 31774291     DOI: 10.1021/acs.jproteome.9b00535

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  4 in total

Review 1.  Metabolomics facilitate the personalized management in inflammatory bowel disease.

Authors:  Rirong Chen; Jieqi Zheng; Li Li; Chao Li; Kang Chao; Zhirong Zeng; Minhu Chen; Shenghong Zhang
Journal:  Therap Adv Gastroenterol       Date:  2021-12-21       Impact factor: 4.409

Review 2.  Reference materials for MS-based untargeted metabolomics and lipidomics: a review by the metabolomics quality assurance and quality control consortium (mQACC).

Authors:  Katrice A Lippa; Juan J Aristizabal-Henao; Richard D Beger; John A Bowden; Corey Broeckling; Chris Beecher; W Clay Davis; Warwick B Dunn; Roberto Flores; Royston Goodacre; Gonçalo J Gouveia; Amy C Harms; Thomas Hartung; Christina M Jones; Matthew R Lewis; Ioanna Ntai; Andrew J Percy; Dan Raftery; Tracey B Schock; Jinchun Sun; Georgios Theodoridis; Fariba Tayyari; Federico Torta; Candice Z Ulmer; Ian Wilson; Baljit K Ubhi
Journal:  Metabolomics       Date:  2022-04-09       Impact factor: 4.747

3.  From urban dust and marine sediment to Ginkgo biloba and human serum-a top ten list of Standard Reference Materials (SRMs).

Authors:  Stephen A Wise
Journal:  Anal Bioanal Chem       Date:  2021-07-21       Impact factor: 4.142

4.  Exploring extra dimensions to capture saliva metabolite fingerprints from metabolically healthy and unhealthy obese patients by comprehensive two-dimensional gas chromatography featuring Tandem Ionization mass spectrometry.

Authors:  Marta Cialiè Rosso; Federico Stilo; Simone Squara; Erica Liberto; Stefania Mai; Chiara Mele; Paolo Marzullo; Gianluca Aimaretti; Stephen E Reichenbach; Massimo Collino; Carlo Bicchi; Chiara Cordero
Journal:  Anal Bioanal Chem       Date:  2020-11-03       Impact factor: 4.142

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.